Phase II clinical trial of VP-16-213 in ovarian cancer.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D005047:Etoposide; D011034:Podophyllotoxin